Granted Patent
B2
US 10,696,673 · App. 16/681,213 · Granted Jun 30, 2020
Bicyclic inhibitors of histone deacetylase
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
Claims (5)
1. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
3. A method of inhibiting HDAC activity in a subject comprising the step of administering to the subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
Assignments (5)
SECURITY INTEREST
Recorded Feb 13, 2026
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073790/0950 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (072656/0509)
Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES, INC.
Reel/Frame 074858/0481 →
SECURITY INTEREST
Recorded Oct 23, 2025
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 072656/0509 →
CHANGE OF NAME
Recorded Dec 1, 2020
From: RODIN THERAPEUTICS, INC.
To: ALKERMES, INC.
Reel/Frame 054504/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 6, 2020
From: FULLER, NATHAN OLIVER; LOWE, JOHN A., III
To: RODIN THERAPEUTICS, INC.
Reel/Frame 051742/0265 →